๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

[Current Topics in Microbiology and Immunology] Advances in multiple Sclerosis and Experimental Demyelinating Diseases Volume 318 || Immunological Aspects of Axon Injury in Multiple Sclerosis

โœ Scribed by Rodriguez, Moses


Book ID
120318740
Publisher
Springer Berlin Heidelberg
Year
2008
Tongue
German
Weight
296 KB
Edition
2008
Category
Article
ISBN
3540736778

No coin nor oath required. For personal study only.

โœฆ Synopsis


Controversy still exists regarding how early disease-modifying agents (DMA) should be commenced and whether all patients with relapsing-remitting MS should in fact be treated. To answer these questions, it is also important to know the natural history of the disease. MS affects nearly 400,000 people in the United States. With their novel, multifaceted approach to basic science, the authors of this book offer help to clinicians and hope to patients.


๐Ÿ“œ SIMILAR VOLUMES


[Current Topics in Microbiology and Immu
โœ Rodriguez, Moses ๐Ÿ“‚ Article ๐Ÿ“… 2008 ๐Ÿ› Springer Berlin Heidelberg ๐ŸŒ German โš– 263 KB

Controversy still exists regarding how early disease-modifying agents (DMA) should be commenced and whether all patients with relapsing-remitting MS should in fact be treated. To answer these questions, it is also important to know the natural history of the disease. MS affects nearly 400,000 people

[Current Topics in Microbiology and Immu
โœ Rodriguez, Moses ๐Ÿ“‚ Article ๐Ÿ“… 2008 ๐Ÿ› Springer Berlin Heidelberg ๐ŸŒ German โš– 200 KB

Controversy still exists regarding how early disease-modifying agents (DMA) should be commenced and whether all patients with relapsing-remitting MS should in fact be treated. To answer these questions, it is also important to know the natural history of the disease. MS affects nearly 400,000 people

[Current Topics in Microbiology and Immu
โœ Rodriguez, Moses ๐Ÿ“‚ Article ๐Ÿ“… 2008 ๐Ÿ› Springer Berlin Heidelberg ๐ŸŒ German โš– 582 KB

Controversy still exists regarding how early disease-modifying agents (DMA) should be commenced and whether all patients with relapsing-remitting MS should in fact be treated. To answer these questions, it is also important to know the natural history of the disease. MS affects nearly 400,000 people

[Current Topics in Microbiology and Immu
โœ Scarisbrick, I. A. (author) ๐Ÿ“‚ Article ๐Ÿ“… 2008 ๐Ÿ› Springer Berlin Heidelberg ๐ŸŒ German โš– 230 KB

Controversy still exists regarding how early disease-modifying agents (DMA) should be commenced and whether all patients with relapsing-remitting MS should in fact be treated. To answer these questions, it is also important to know the natural history of the disease. MS affects nearly 400,000 people

[Current Topics in Microbiology and Immu
โœ Scarisbrick, I. A. (author) ๐Ÿ“‚ Article ๐Ÿ“… 2008 ๐Ÿ› Springer Berlin Heidelberg ๐ŸŒ German โš– 230 KB

Controversy still exists regarding how early disease-modifying agents (DMA) should be commenced and whether all patients with relapsing-remitting MS should in fact be treated. To answer these questions, it is also important to know the natural history of the disease. MS affects nearly 400,000 people